---
pmid: '23597562'
title: Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor
  blocker with allosteric properties.
authors:
- Bono F
- De Smet F
- Herbert C
- De Bock K
- Georgiadou M
- Fons P
- Tjwa M
- Alcouffe C
- Ny A
- Bianciotto M
- Jonckx B
- Murakami M
- Lanahan AA
- Michielsen C
- Sibrac D
- Dol-Gleizes F
- Mazzone M
- Zacchigna S
- Herault JP
- Fischer C
- Rigon P
- Ruiz de Almodovar C
- Claes F
- Blanc I
- Poesen K
- Zhang J
- Segura I
- Gueguen G
- Bordes MF
- Lambrechts D
- Broussy R
- van de Wouwer M
- Michaux C
- Shimada T
- Jean I
- Blacher S
- Noel A
- Motte P
- Rom E
- Rakic JM
- Katsuma S
- Schaeffer P
- Yayon A
- Van Schepdael A
- Schwalbe H
- Gervasio FL
- Carmeliet G
- Rozensky J
- Dewerchin M
- Simons M
- Christopoulos A
- Herbert JM
- Carmeliet P
journal: Cancer Cell
year: '2013'
full_text_available: false
doi: 10.1016/j.ccr.2013.02.019
---

# Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.
**Authors:** Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M, Jonckx B, Murakami M, Lanahan AA, Michielsen C, Sibrac D, Dol-Gleizes F, Mazzone M, Zacchigna S, Herault JP, Fischer C, Rigon P, Ruiz de Almodovar C, Claes F, Blanc I, Poesen K, Zhang J, Segura I, Gueguen G, Bordes MF, Lambrechts D, Broussy R, van de Wouwer M, Michaux C, Shimada T, Jean I, Blacher S, Noel A, Motte P, Rom E, Rakic JM, Katsuma S, Schaeffer P, Yayon A, Van Schepdael A, Schwalbe H, Gervasio FL, Carmeliet G, Rozensky J, Dewerchin M, Simons M, Christopoulos A, Herbert JM, Carmeliet P
**Journal:** Cancer Cell (2013)
**DOI:** [10.1016/j.ccr.2013.02.019](https://doi.org/10.1016/j.ccr.2013.02.019)

## Abstract

1. Cancer Cell. 2013 Apr 15;23(4):477-88. doi: 10.1016/j.ccr.2013.02.019.

Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF 
receptor blocker with allosteric properties.

Bono F(1), De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, 
Alcouffe C, Ny A, Bianciotto M, Jonckx B, Murakami M, Lanahan AA, Michielsen C, 
Sibrac D, Dol-Gleizes F, Mazzone M, Zacchigna S, Herault JP, Fischer C, Rigon P, 
Ruiz de Almodovar C, Claes F, Blanc I, Poesen K, Zhang J, Segura I, Gueguen G, 
Bordes MF, Lambrechts D, Broussy R, van de Wouwer M, Michaux C, Shimada T, Jean 
I, Blacher S, Noel A, Motte P, Rom E, Rakic JM, Katsuma S, Schaeffer P, Yayon A, 
Van Schepdael A, Schwalbe H, Gervasio FL, Carmeliet G, Rozensky J, Dewerchin M, 
Simons M, Christopoulos A, Herbert JM, Carmeliet P.

Author information:
(1)Early to Candidate Department and Lead Generation and Candidate Realization 
Department, Sanofi, 31036 Toulouse, France.

Receptor tyrosine kinases (RTK) are targets for anticancer drug development. To 
date, only RTK inhibitors that block orthosteric binding of ligands and 
substrates have been developed. Here, we report the pharmacologic 
characterization of the chemical SSR128129E (SSR), which inhibits fibroblast 
growth factor receptor (FGFR) signaling by binding to the extracellular FGFR 
domain without affecting orthosteric FGF binding. SSR exhibits allosteric 
properties, including probe dependence, signaling bias, and ceiling effects. 
Inhibition by SSR is highly conserved throughout the animal kingdom. Oral 
delivery of SSR inhibits arthritis and tumors that are relatively refractory to 
anti-vascular endothelial growth factor receptor-2 antibodies. Thus, 
orally-active extracellularly acting small-molecule modulators of RTKs with 
allosteric properties can be developed and may offer opportunities to improve 
anticancer treatment.

Copyright Â© 2013 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2013.02.019
PMID: 23597562 [Indexed for MEDLINE]
